|
|
617 million
|
The number of proteins in a new tool devised by Meta AI - the artificial intelligence arm of Facebook parent Meta - that could help researchers in the hunt for new drugs.
|
|
|
|
|
|
“As a healthcare system, it’s fun to do something different."
|
— Lori Williams, associate director of marketing at University of Utah Health, on their "Vas Madness" program that promotes the convenience of doing vasectomies during the NCAA basketball tournament.
|
|
|
|
|
|
|
|
Photographs by F. Martin Ramin/The Wall Street Journal; Food Styling by Mieko Takahashi
|
|
|
|
The surprise villain of U.S. diets: sandwiches. Sandwiches are the number one source of sodium and saturated fat in Americans’ diets, according to federal data. Nutritionists, doctors and public-health officials are trying to nudge people to make their sandwiches healthier. Think, less processed meat, more lettuce. Read more.
|
|
-
Science-Backed Strategies That Will Actually Help You Eat Better (Read)
|
|
Prostate cancer patients could forgo radical treatment. Men with localized prostate cancer could safely choose surveillance over surgery or radiation, according to a study of 1,600 men in the U.K. Mortality was low whether patients received radiotherapy, a prostatectomy or active monitoring, with similar death rates across all three groups. Read more.
|
|
-
More Women With Breast Cancer Could Skip Harsh Radiation (Read)
|
|
What's wrong with doctor-rating websites. Most lack information on convictions, medical malpractice claims and other disciplinary actions, research shows. And doctors who have passed away can still linger on sites. Read more.
|
|
|
|
|
PHOTO: BESS ADLER/BLOOMBERG NEWS
|
|
|
|
Pfizer's $43 billion deal to buy a cancer biotech. The agreement to buy Seagen expands Pfizer's cancer footprint at a time when it is looking to offset expected sales declines. It's also an early sign that, despite the threat of close antitrust examinations and higher interest rates, big pharmaceutical companies are poised for heavy deal-making this year. Read more.
|
|
-
Why Seagen Was a Takeover Target (Read)
-
Big Pharma Executives Say They Are Hunting for Deals Again (Read)
-
🎥 Pfizer CEO on the Post-Covid Roadmap for Pharma (Watch)
|
|
Biotech and Silicon Valley Bank: About 12% of the failed bank's client deposits of $173 billion came from the life sciences and healthcare sector. This week, many of those companies struggled to get access to their funds in a scramble to make payroll. (Read)
|
|
VA to cover Alzheimer’s drug Leqembi. Veterans Affairs will be the first major insurer to cover Esai Co.'s new Alzheimer's drug since it was approved earlier this year. Leqembi is expected to have relatively small sales unless Medicare modifies a decision that denies routine coverage of drugs in this class. Read more.
|
|
Drugmakers to slash insulin prices. Sanofi and Novo Nordisk this week joined Eli Lilly in announcing they would cut the list prices of their insulin drugs, some by more than 70%. Sanofi also said it would cap a Lantus patient’s monthly out-of-pocket cost at $35. Read more.
|
|
-
U.S. Names First Drugs to Face Medicare Price-Hike Penalty (Read)
|
|
|
This newsletter was compiled by the WSJ’s Health & Science team. Follow us on Twitter @WSJHealth and @WSJScience. Email us by replying to this newsletter.
|
|
|
|
|